Fitbit to launch first ECG app in U.S., Europe next month

The Sense smartwatch carries a thermometer and a sensor to measure changes in the electrical conductivity of the skin—a trait famously employed in polygraph lie-detector tests, but in this case used to help the wearer track and manage their stress levels. (Fitbit)

Fitbit’s latest smartwatch has now secured medical device clearances in the U.S. and Europe, unlocking the full use of its ECG app to help identify cases of the irregular heart rhythm known as atrial fibrillation.

With an FDA green light and a CE mark, the app for the Fitbit Sense will launch in the U.S. and certain European countries as well as in Hong Kong and India starting in October.

“Helping people understand and manage their heart health has always been a priority for Fitbit, and our new ECG app is designed for those users who want to assess themselves in the moment and review the reading later with their doctor,” said Fitbit co-founder and Chief Technology Officer Eric Friedman.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Following a long line of heart-rate trackers, Fitbit unveiled its new Sense smartwatch in late August as its first wearable to feature an ECG function. By holding their fingers to the stainless steel ring on the face of the watch, a user can take a 30-second, single-lead reading of their heart’s electrical activity—performing a spot-check if they notice any unusual cardiac symptoms.

Atrial fibrillation can be difficult to detect early, before the rapid, abnormal rhythm can lead to serious complications such as stroke, with many people finding out they have afib only after one has occurred.

RELATED: Fitbit posts early findings showing its trackers can identify cases of COVID-19 before symptoms take hold

“Physicians are often flying blind as to the day-to-day lives of our patients in between office visits,” said Venkatesh Raman, an interventional cardiologist at MedStar Georgetown Hospital, who served as principal investigator for Fitbit’s ECG app clinical study in the U.S. “I’ve long believed in the potential for wearable devices to help us stay better connected, and use real-world, individual data to deliver more informed, personalized care.” 

The nationwide study showed that the watch’s ECG algorithm was able to correctly rule out participants with a normal heart rhythm 100% of the time, while detecting 98.7% of afib cases.

The Sense smartwatch also carries a thermometer and a sensor to measure changes in the electrical conductivity of the skin—a trait famously employed in polygraph lie-detector tests, but in this case used to help the wearer track and manage their stress levels.

RELATED: Fitbit launches broad virtual AFib study using all its heart-tracking devices

Earlier this year, Fitbit launched a large study to explore the ability of its more common heart rate tracking technology—photoplethysmography, or PPG, via light-based sensors tracking blood flow through the skin—to detect irregular heart rhythms that could be linked to afib. 

Since May, the company has enrolled more than 400,000 participants. If successful, the company could potentially roll out afib detection to a wider range of its wearable fitness trackers.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.